Trial of AEO in New Glioblastoma (GBM)

NCT ID: NCT04450160

Last Updated: 2020-06-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-31
• Study Completion Date: 2022-09-30

Brief Summary

This is a multicenter, Phase 2, Proof-of-concept study in subjects with newly diagnosed glioblastoma multiforme (GBM).

All subjects will receive standard of care therapy for the treatment of their GBM and any Anti-Epileptic Drug (AED) deemed necessary for their surgical resection of the GBM. Patients who are taking concomitant AEDs will be eligible for the study. Treatment with Anhydrous Enol-Oxaloacetate will be added to the Standard of Care.

This study is testing adjuvant Anhydrous Enol-Oxaloacetate (AEO) in GBM, an orally active drug candidate which in animal studies has demonstrated decreased tumor growth rate and increased survival.

Detailed Description

Currently, the multidisciplinary Standard of Care treatment for Glioblastoma multiforme includes maximal surgical resection of the tumor followed by radiotherapy plus concomitant and maintenance temozolomide chemotherapy.This study will treat newly diagnosed GBM patients by adding Anhydrous Enol-Oxaloacetate treatment to their current Standard of Care.

In the body, Anhydrous Enol-Oxaloacetate (AEO) converts into "Oxaloacetate", a metabolite important for many biochemical reactions in the body. On a cellular level, oxaloacetate treatment has been found to modify cancer metabolism in GBM cells, reversing the "Warburg Effect", reducing glycolysis and reducing lactate production. In animals, oxaloacetate treatment has increased survival and reduced tumor growth of implanted GBM tumors.

In other animal studies, oxaloacetate has also shown to have neuo-protective effects including positive effects on seizure development.

.

Conditions

Glioblastoma Multiforme

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard of Care

Current GBM Treatment of surgery, radiation and chemotherapy with temozolomide.

Group Type: PLACEBO_COMPARATOR

Standard of Care

Intervention Type: OTHER

Standard of Care Temozolomide

AEO with Standard of Care

Anhydrous Enol-Oxaloacetate added to the Standard of Care (surgery, radiation and chemotherapy with temozolomide).

Group Type: EXPERIMENTAL

Anhydrous Enol-Oxaloacetate (AEO)

Intervention Type: DRUG

Oral supplementation with AEO along with the Standard of Care (Temozolomide)

Standard of Care

Intervention Type: OTHER

Standard of Care Temozolomide

Interventions

Anhydrous Enol-Oxaloacetate (AEO)

Oral supplementation with AEO along with the Standard of Care (Temozolomide)

Intervention Type: DRUG

Standard of Care

Standard of Care Temozolomide

Intervention Type: OTHER

Other Intervention Names

Chemotherapy with Temozolomide

Eligibility Criteria

Inclusion Criteria

• • Histopathologic diagnosis of glioblastoma multiforme

• Standard of care maximal feasible surgical resection of the glioma
• Post-operative pre-enrollment MRI-Note: measurable disease is not required
• Concomitant anti-epileptic drugs
• Hemoglobin >9 g/dL
• Platelets >100,000/microliter (mcL)
• <3.0 Upper Limit of Normal Range (ULN) for Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and/or Alkaline Phosphatase
• <2.0 Upper Limit of Normal Range (ULN) for serum creatinine
• Karnofsky performance status >70
• Mentally competent to follow study procedures
• Male and female patients of childbearing potential must agree to use a dual method of contraception (a highly effective method of contraception in conjunction with barrier contraception) consistently and correctly from the first dose of study drug until 90 days after the last dose of study drug
• Able to answer questions on the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire
• Subject is willing and able to give informed consent and to follow instructions as per the protocol

Exclusion Criteria

• • Concomitant treatment with carmustine wafers or tumor-treating electric fields (TTFields)

• QT Interval corrected with the fridericia formula (QTcF) >480ms
• Significant concurrent illness / disease
• Predicted life expectancy < 6 months from date of randomization
• Pregnancy
• Enrollment in another clinical trial during the course of the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MetVital, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Alan B Cash, MS

Role: CONTACT

acash@MetVital.com

858-947-5722

References

Augur ZM, Doyle CM, Li M, Mukherjee P, Seyfried TN. Nontoxic Targeting of Energy Metabolism in Preclinical VM-M3 Experimental Glioblastoma. Front Nutr. 2018 Oct 5;5:91. doi: 10.3389/fnut.2018.00091. eCollection 2018.

Reference Type: BACKGROUND

PMID: 30349820 (View on PubMed)

Ruban A, Berkutzki T, Cooper I, Mohar B, Teichberg VI. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Invest New Drugs. 2012 Dec;30(6):2226-35. doi: 10.1007/s10637-012-9799-5.

Reference Type: BACKGROUND

PMID: 22392507 (View on PubMed)

Yamamoto HA, Mohanan PV. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol Lett. 2003 Jul 20;143(2):115-22. doi: 10.1016/s0378-4274(03)00114-0.

Reference Type: BACKGROUND

PMID: 12749815 (View on PubMed)

Other Identifiers

Terra-001-201

Identifier Type: -

Identifier Source: org_study_id